Australia markets closed

Kyowa Kirin Co., Ltd. (KYKOF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
22.950.00 (0.00%)
At close: 09:38AM EST
Full screen
Trade prices are not sourced from all markets
Previous close22.95
Open22.95
Bid0.00 x 0
Ask0.00 x 0
Day's range22.95 - 22.95
52-week range21.22 - 28.78
Volume6
Avg. volume128
Market cap12.621B
Beta (5Y monthly)0.23
PE ratio (TTM)24.95
EPS (TTM)0.92
Earnings dateN/A
Forward dividend & yield0.42 (1.82%)
Ex-dividend date29 Dec 2022
1y target estN/A
  • Business Wire

    Grünenthal and Kyowa Kirin International Announce Joint Venture Collaboration for Established Medicines Portfolio

    AACHEN, Germany & TOKYO, November 24, 2022--Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company, are today announcing they have signed a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio. The Joint Venture Collaboration comprises 13 brands across 6 therapeutic

  • PR Newswire

    New Effort Sheds Light on Burdens and Benefits of Parkinson's Care Partner Experience, Offers Insights for Navigating Journey

    Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company, today announced the publication of Burden and Benefit: Embracing the duality of the Parkinson's caregiving experience, a whitepaper that explores the caregiving experience, featuring insights from the 2022 Parkinson's Care Partner Survey and advice from advocates and care partners on how to plan for the road ahead. The survey and whitepaper were developed in partnership w

  • Business Wire

    MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022

    SAN DIEGO & TOKYO, November 03, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that three abstracts highlighting data and information from the clinical development program evaluating the intermittent dosing of zandelisib, an investigational